logo
Plus   Neg
Share
Email

Regulus Therapeutics Advances Orphan Disease Portfolio For Alport Syndrome

Regulus Therapeutics Inc. (RGLS) said it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical development, RG-012, an anti-miR targeting microRNA-21 ("miR-21") to treat Alport Syndrome, a life-threatening, genetic kidney disease with no approved therapy.

RG-012 has a very favorable preclinical profile to date which Regulus believes supports clinical studies in man. RG-012 is a potent inhibitor of miR-21 in both in vitro and in vivo preclinical models.

The company said in a statement, "Subcutaneous administration of RG-012 has significantly reduced the rate of renal fibrosis and improved the lifespan of the mice up to 50% in a mouse model of Alport Syndrome, which we believe is a good surrogate for the human disease."

Regulus believes that these preclinical survival results may translate to a similar increased lifespan in human patients. Furthermore, RG-012 has been well tolerated to date with a favorable pharmacokinetic profile that supports the potential for a once/week dosing regimen.

Neil W. Gibson, Ph.D., Regulus' Chief Scientific Officer noted, "We believe that RG-012 may become a transformative treatment for patients with Alport Syndrome, a life-threatening, genetic disease with significant unmet medical need. We are currently performing additional preclinical studies and finalizing development plans for RG-012 and expect to enter clinical development in the first half of 2015."

Regulus is responsible for advancing RG-012 to proof-of-concept. At that stage of development, Regulus' strategic alliance partner, Sanofi, has an exclusive option exercisable after proof-of-concept to assume all costs, responsibilities and obligations for further development and commercialization of RG-012.

Sanofi would reimburse Regulus for a significant portion of its preclinical and clinical development costs and would pay Regulus an option exercise fee, provided Sanofi chooses to exercise its option on RG-012. Regulus is eligible to receive development and commercialization milestone payments and would have an option to co-promote in the U.S. or receive royalty payments in the mid 10% - 20% range.

Alport Syndrome is a genetic condition caused by mutations in the COL4A3, COL4A4, and COL4A5 genes that is characterized by kidney disease, hearing loss, and eye abnormalities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nestle Prepared Foods, part of Swiss food and beverage giant Nestle SA, has recalled around 762,615 pounds of not-ready-to-eat or NRTE pepperoni hot pockets as it might be contaminated with extraneous materials including glass and hard plastic, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. Lake Champlain Chocolates or LCC has recalled select LCC milk chocolate products citing the possible presence of foreign objects, mainly brittle plastic pieces, according to the U.S. Food and Drug Administration. The affected products include Hazelnut Five Star Bar; Fruit & Nut Five Star Bar; Almond Five Star Bar; Granola Five Star Bar... A public health alert has been issued for ready-to-eat or RTE beef jerky products by the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS. The warning is given due to misbranding and the presence of undeclared anchovies, a known allergen. A recall was not requested because the products are not currently available for sale to consumers.
RELATED NEWS
Follow RTT